This week's Fierce Pharma is brought to you by Clarivate.

Leading Innovators in Gene Editing

The Next Chapter for Gene Editing

Gene editing is entering an era of unprecedented innovation. Following the FDA’s landmark approvals of Casgevy and Lyfgenia, the future of this groundbreaking field is brimming with potential—and challenges. Our latest whitepaper provides an in-depth look at the startups, targets, and trends driving the next wave of gene editing therapeutics. What you’ll uncover:

• Emerging startups making waves with novel approaches to gene editing.
• Targets and indications paving the way for transformative therapies.
• Key challenges—clinical, regulatory, and market access hurdles to overcome.
• Implications for regulators, payers, clinicians, and patients alike.

Gene editing’s journey has only just begun. Stay ahead of the curve with insights into the companies and innovations shaping the future. Be the first to know what’s next in gene editing.